Application Data
(Antibody Neutralization Assay with SARS-CoV-2-614G Pseudoviral ParticlesASSAY PROTOCOLNote: require a firefly luciferase assay kit (Catalog # is for the 384-well plate. Use 4x of the volumes for the 96-well plate.Cell Infection:1. Count HEK293-ACE2 cells (Catalog # to be infected and seed ~7.5K cells per well into 384-well plates (15 ul per well) in DMEM with 10% HyClone™ FetalClone™ II Serum (no antibiotics).2. On the 2nd day, dilute the antibodies (5X of the final concentrations) in DMEM with 10% HyClone™ FetalClone™ II Serum (no antibiotics).Note: for most antibodies, we recommend testing 11 different doses (1:3 serial dilutions), starting from 30 ug/ml or 10 ug/ml (final concentration in the well).3. Take 4 ul of the antibody solution and add into a compound plate containing 10 ul of SARS-CoV-2 PP per well (i.e. SARS-CoV-2 the 614G variant PP, Catalog # Incubate at 37 degree C for 1 hr.5. Take a cell plate out from the incubator, remove the medium, add 17.5 ul 14 of SARS-CoV-2 PP and antibody mix into each well of the cell plate. Centrifuge at 700 rpm for 15 min at 4 degree C.6. Add additional 6 ul of DMEM with 10% FC into each well.7. Incubate at 37 degree C for 42 hr.Measurement of Luciferase Activity in Infected cells1. Do not remove the medium. Add 20 ul luciferase assay WORKING SOLUTION into each well. Refer to the protocol of Read in a luminescence plate reader and record the data.)
COVID 19 Pseudoviral Particles, Omicron-XBB Coronavirus Pseudovirus | COVID-19 pseudovirus
SARS-CoV-2 Pseudoviral Particles, Omicron-XBB Variant
Easy to use: Amenable to HTS format (96-well, 384-well and 1536-well format)
*Note: read the instruction for thawing in the following protocol carefully. Do not aliquot and refreeze.
Shipping: Ships on Dry Ice.
Application Data
(Antibody Neutralization Assay with SARS-CoV-2-614G Pseudoviral ParticlesASSAY PROTOCOLNote: require a firefly luciferase assay kit (Catalog # is for the 384-well plate. Use 4x of the volumes for the 96-well plate.Cell Infection:1. Count HEK293-ACE2 cells (Catalog # to be infected and seed ~7.5K cells per well into 384-well plates (15 ul per well) in DMEM with 10% HyClone™ FetalClone™ II Serum (no antibiotics).2. On the 2nd day, dilute the antibodies (5X of the final concentrations) in DMEM with 10% HyClone™ FetalClone™ II Serum (no antibiotics).Note: for most antibodies, we recommend testing 11 different doses (1:3 serial dilutions), starting from 30 ug/ml or 10 ug/ml (final concentration in the well).3. Take 4 ul of the antibody solution and add into a compound plate containing 10 ul of SARS-CoV-2 PP per well (i.e. SARS-CoV-2 the 614G variant PP, Catalog # Incubate at 37 degree C for 1 hr.5. Take a cell plate out from the incubator, remove the medium, add 17.5 ul 14 of SARS-CoV-2 PP and antibody mix into each well of the cell plate. Centrifuge at 700 rpm for 15 min at 4 degree C.6. Add additional 6 ul of DMEM with 10% FC into each well.7. Incubate at 37 degree C for 42 hr.Measurement of Luciferase Activity in Infected cells1. Do not remove the medium. Add 20 ul luciferase assay WORKING SOLUTION into each well. Refer to the protocol of Read in a luminescence plate reader and record the data.)
Application Data
(Antibody Neutralization Assay with SARS-CoV-2-614G Pseudoviral ParticlesASSAY PROTOCOLNote: require a firefly luciferase assay kit (Catalog # is for the 384-well plate. Use 4x of the volumes for the 96-well plate.Cell Infection:1. Count HEK293-ACE2 cells (Catalog # to be infected and seed ~7.5K cells per well into 384-well plates (15 ul per well) in DMEM with 10% HyClone™ FetalClone™ II Serum (no antibiotics).2. On the 2nd day, dilute the antibodies (5X of the final concentrations) in DMEM with 10% HyClone™ FetalClone™ II Serum (no antibiotics).Note: for most antibodies, we recommend testing 11 different doses (1:3 serial dilutions), starting from 30 ug/ml or 10 ug/ml (final concentration in the well).3. Take 4 ul of the antibody solution and add into a compound plate containing 10 ul of SARS-CoV-2 PP per well (i.e. SARS-CoV-2 the 614G variant PP, Catalog # Incubate at 37 degree C for 1 hr.5. Take a cell plate out from the incubator, remove the medium, add 17.5 ul 14 of SARS-CoV-2 PP and antibody mix into each well of the cell plate. Centrifuge at 700 rpm for 15 min at 4 degree C.6. Add additional 6 ul of DMEM with 10% FC into each well.7. Incubate at 37 degree C for 42 hr.Measurement of Luciferase Activity in Infected cells1. Do not remove the medium. Add 20 ul luciferase assay WORKING SOLUTION into each well. Refer to the protocol of Read in a luminescence plate reader and record the data.)
Application Data
(Figure 2. Pseudoviral Particle (PP) Infection Assays (SARS-CoV-2 Omicron XBB variant pseudoviral particles on HEK293-ACE2 cells) (Luminescence plate reader: BioTek Synergy 2)Legends: XBB: SARS-CoV-2 Omicron XBB variant MLV pseudovirus particles (AAA13795)(-): MLV control (w/o envelope spike protein)(Catalog # 1. Illustration of the replication-deficient MLV particle pseudotyped with SARS-CoV-2 Spike protein)
Application Data
(Figure 2. Pseudoviral Particle (PP) Infection Assays (SARS-CoV-2 Omicron XBB variant pseudoviral particles on HEK293-ACE2 cells) (Luminescence plate reader: BioTek Synergy 2)Legends: XBB: SARS-CoV-2 Omicron XBB variant MLV pseudovirus particles (AAA13795)(-): MLV control (w/o envelope spike protein)(Catalog # 1. Illustration of the replication-deficient MLV particle pseudotyped with SARS-CoV-2 Spike protein)
Our SARS-CoV-2 Omicron XBB Pseudoviral Particles are replication-deficient MLV pseudotyped with the SARS-CoV-2 spike protein of the Omicron XBB sub-variant (GISAID ID: EPI_ISL_15919016). They also contain the ORF for firefly luciferase as a reporter. They establish a pseudovirus cell entry assay mediated by the SARS-CoV-2 spike protein that can be conveniently measured via luciferase reporter activity. This pseudovirus assay isolates the SARS-CoV-2 viral entry from other steps of the viral infection cycle.
Similar Products
Product Notes
The COVID-19 (Catalog #AAA13795) is a Pseudovirus and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "COVID 19 Pseudoviral Particles, Omicron-XBB Coronavirus, Pseudovirus" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.